The 6 identified predictors were repeatedly found as relevant even for long-term outcome studies in first- and multiple-episode patients.55,57-59 This finding underlines that predictors
of remission are also relevant for the overall outcome in schizophrenia.51 This conclusion is partly supported by studies, which assessed predictors of remission, functional remission, and adequate quality of life/subjective well-being simultaneously Inhibitors,research,lifescience,medical in a single patient cohort. Lambert et al33,47 and Novick et al60 analyzed predictors of these three outcome dimensions within the SOHO (Schizophrenia Outpatient Health Outcome) study at 233 and 3 years’ follow-up.47,60 Overall, symptomatic remission was mainly predicted by baseline, better functioning level at baseline, early symptomatic improvement, medication adherence and remitted substance use; functional remission by younger Inhibitors,research,lifescience,medical age, better functioning level at baseline and early functional remission; and adequate quality of life by younger age, lower illness severity at baseline, Inhibitors,research,lifescience,medical better functioning level at baseline, early symptomatic and quality of life remission, and medication adherence. Full remission (fulfilling all three dimensions
for ≥6 months) and recovery (fulfilling all three dimensions for ≥24 months) was mainly predicted by younger age, better functioning level at baseline, and early improvement within all three outcome dimensions. Therefore, these Inhibitors,research,lifescience,medical results suggest that predictors of symptomatic remission are partly also predictors for the overall outcome in schizophrenia with baseline functioning playing an important predictive role. Several limitations of these findings have to be addressed: (i) results are hampered by a large variation Inhibitors,research,lifescience,medical regarding aspects such as sample selection and
collection, assessment methods used or duration of study period; (ii) aspects of type and intensity of treatment are rarely assessed. The meta-analysis of selleck chemical Menezes et al56 of 37 longitudinal outcome studies of first-episode nonaffective psychosis highlights the importance of these two aspects. They failed to confirm previously reported variables such as duration of untreated psychosis or age at onset as significant outcome predictors, and found that a favorable almost outcome were mainly related to combined pharmacotherapeutic and psychosocial interventions as well as lack of epidemiologic representativeness of the sample. These findings suggest that future studies on remission and its predictors should control for treatment aspects and should aim to assess cohorts as representative as possible. Table IV. Most relevant predictors of remission defined as severity and time criteria as proposed by Andreasen et al1 (sorted according to duration of trial). (1) These studies used CGI-Schizophrenia criteria (CGI-SCH overall, positive, negative, cognitive and …
Related posts: